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Abstract: The study of cell lines by nuclear magnetic resonance (NMR) spectroscopy metabolomics
represents a powerful tool to understand how the local metabolism and biochemical pathways
are influenced by external or internal stimuli. In particular, the use of adherent mammalian
cells is emerging in the metabolomics field in order to understand the molecular mechanism of
disease progression or, for example, the cellular response to drug treatments. Hereto metabolomics
investigations for this kind of cells have generally been limited to mass spectrometry studies. This
study proposes an optimized protocol for the analysis of the endo-metabolome of human colon cancer
cells (HCT116) by NMR. The protocol includes experimental conditions such as washing, quenching
and extraction. In order to test the proposed protocol, it was applied to an exploratory study of cancer
cells with and without treatment by anti-cancer drugs, such as DNA G-quadruplex binders and
Adriamycin (a traditional anti-cancer drug). The exploratory NMR metabolomics analysis resulted in
NMR assignment of all endo-metabolites that could be detected and provided preliminary insights
about the biological behavior of the drugs tested.
Keywords: cell metabolomics; colon cancer; NMR spectroscopy; Multivariate statistical analysis;
G-quadruplex ligands
1. Introduction
In the last decades, metabolomics studies have been performed on different biofluids (e.g., plasma,
serum, urine, saliva, lymph and cerebrospinal fluid) with successful results, showing applications in
many areas, such as biomarker discovery, clinical studies, nutritional studies, drug efficacy and toxicity
evaluations and disease diagnosis [1–4]. However, recent developments in the use of metabolomics
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involve the characterization and interpretation of the cell metabolome, starting from prokaryotes
(especially Escherichia coli) to eukaryotes cell lines (yeast or mammalian cells) [5,6]. Complementary to
the classic biofluid analyses, the metabolomic profiles of cells represent a powerful tool to understand
how the local metabolism and biochemical pathways are influenced by pathologies and by external
or internal stimuli. In particular, the metabolome analysis of cells grown in vitro provides important
information for the development of models of biological pathways and networks. In vitro cell
metabolomics analysis offers several advantages: experimental variables are easier to control, higher
reproducibility, less expensive and easier to interpret than analysis of animal models and human
subjects [7]. The use of mammalian cells is emerging in the metabolomics field in order to understand
the molecular mechanism of disease progression, the cellular response to drug treatments [8] and
the cell culture monitoring [9]. In particular, the identification and characterization of cancer cell
metabolomic signature may play an important role in the early diagnosis as well as in the following
therapeutic response, making it possible to map the drug action into metabolic pathways [10].
Colon carcinoma is the third most commonly diagnosed cancer in the world and the second most
common cause of death from cancer [11]. Surprisingly, few metabolomic studies dealing with colon
carcinoma cell lines are reported in the literature [12–16]. The analysis of metabolic profiles of this
cell line provides a comprehensive assessment of the alterations in the metabolite levels in cells and
can produce important information on in vitro actions of drugs towards their incorporation into novel
therapeutic settings.
Recently, targeting of DNA secondary structures, for example G-quadruplexes, has been
considered as an appealing opportunity for drug intervention in anti-cancer therapy [17]. G-quadruplex
DNA (G4-DNA) structures are four-stranded helical DNA (or RNA) structures, comprising stacks
of G-tetrads, which are the outcome of planar association of four guanines in a cyclic Hoogsteen
hydrogen-bonding arrangement. From the biological point of view, G4-DNAs are widespread in the
genome and they are present in the promoters of a wide range of genes, important in cell signaling,
and recognized as hallmarks of cancer: c-Myc, c-Kit and K-Ras (self-sufficiency); pRb (insensitivity);
Bcl-2 (evasion of apoptosis); VEGF-A (angiogenesis); hTERT (limitless replication); and PDGFA
(metastasis) [18]. The G4-DNAs are also found in telomeric regions of the chromosome [19]. Telomeric
DNA consists of tandem repeats of a simple short sequence, rich in guanine residues (TTGGGA).
Telomeres protect the ends of the chromosome from damage and recombination, and their shortening
is implicated in cellular senescence. The elongation of telomeric DNA, operated by the enzyme
telomerase, leads cancer cells towards an infinite lifetime. The inhibition of telomerase, which is
over-expressed in about 85% of tumors, represents the forefront of research for new effective anti-cancer
drugs. Since this enzyme requires a single stranded telomeric primer, the formation of G-quadruplex
complexes by telomeric DNA inhibits the telomerase activity. In this respect, it has been found that
small molecules that stabilize G-quadruplex structures are effective telomerase inhibitors and can be
considered as novel drugs candidates for anti-cancer therapy [20]. Recently, it has been discovered
that a number of G-quadruplex ligands are exerting interesting antitumor activity in vitro [21,22].
Since the G-quadruplex ligands may be important for the development of new anti-cancer agents,
this study is aimed to verify the feasibility of a NMR metabolomics study of HCT116 cells when treated
with these agents. In particular, the treatment with compound 1, which is one of the most promising
ligands discovered by virtual screening calculations [23] (Figure 1), was compared to the treatment
with pentacyclic acridine RHPS4 (2) (Figure 1), which is one of the most studied G4 ligands [24],
and to treatment using the well-known antitumor agent Adriamycin (3) (Figure 1). Adriamycin is
an approved chemotherapeutic agent with strong activity against a wide range of human malignant
neoplasms including acute leukemia, non-Hodgkin lymphomas, breast cancer, Hodgkin’s disease and
sarcomas [25]. Thus, this study describes an optimized protocol for NMR metabolomics of adherent
mammalian cell lines and the preliminary application and validation to treated cancer cells.
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purchased from Gibco (NY, USA). Fetal bovine serum (FBS) was purchased from Thermo Scientific 
(HyCloneTM). Crystal phosphate buffer saline (PBS) (0.01 M Phosphate buffer, 0.0027 M KCl e 0.14 
M NaCl, pH 7.4 at 25 °C) was purchased from Bioline (TR, Italy). 
Deuterium oxide (D2O, 99.8%D) was obtained from Sigma-Aldrich (St. Louis, MO, USA). All 
other reagents were of analytical grade. 
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in parallel in multiple (3×) 150 mm tissue culture dishes (Corning). Upon achievement of 90% cellular 
confluency, the culture medium (15 mL) was removed and the cells were processed for the endo-
metabolomic analysis. In brief, the cells were extensively washed (4 times) with ice-cold phosphate-
buffered saline (PBS 1X) in order to completely remove any residue of culture medium. Afterwards, 
5.4 mL of PBS were added to each culture dish and cells were collected by scraping with a rubber 
policeman. Finally, the cells were counted, placed in Falcon tubes and the final PBS volumes were 
adjusted to obtain 15 × 106 cells into 5.4 mL PBS (pH 7.4). On the other side, the culture medium of 
each cell growth was collected and immediately stored at −80 °C to be used, in the close future, for 
the exo-metabolome analyses. 
2.3. Anti-Cancer Drug Treatments 
The dose and drug exposure duration time of cell culture for compounds 1 and 2 were 
established according to the literature (IC50) [26], while the optimal conditions for compound 3 were 
chosen on the basis of in-house unpublished results. In order to have a unique group of untreated 
control cells valid for all three treatments, compounds 1 and 2 were added to cell cultures 24 h after 
seeding. Cells were exposed to the drug treatment for 72 h with 1 μM final concentration; compound 
3 was added to cell cultures 80 h after seeding. In this case, the drug exposure of cell cultures was for 
16 h with 0.1 μM final concentration. Thus, all the cells (including controls) were detached from the 
plates after 96 h. 
  
Figure 1. The structure of compound (1), RHPS4 (2), the str cture of the tradi ional antitumor
agent Adriamycin (3).
2. Materials and Methods
2.1. Materials
HCT116 cells were purchased from America Type Culture Collecti n (ATCC–Manassas, VA,
USA). High glucose Dulbecco’s Modified Eagle’s medium (DMEM/HIGH Glucose) with L-Glutamine
was purchased from Euroclone (MI, Italy), penicillin–streptomycin solution for cell culture was
purchased from Gibco (NY, USA). Fetal bovine serum (FBS) was purchased from Thermo Scientific
(HyCloneTM). Crystal phosphate buffer saline (PBS) (0.01 M Phosphate buffer, 0.0027 M KCl e 0.14 M
NaCl, pH 7.4 at 25 ˝C) was purchased from Bioline (TR, Italy).
Deuterium oxide (D2O, 99.8%D) was obtained from Sigma-Aldrich (St. Louis, MO, USA).
All other reagents were of analytical grade.
2.2. Cell Culture
The HTC116 cells were grown in high glucose (4.5 g/L) Dulbecco’s Mo ified Eagle’s Medium
(DMEM/HIGH Glucose, Euroclone) supplemented with 10% FBS, L-Glutamine (2 mM), penicillin
(100 U/mL) and streptomycin (1 mg/mL), at 37 ˝C in a humidified atmosphere of 5% CO2. In
order to obtain the final desired number of cells (1.5 ˆ 106) for each treatment, the cell growth was
carried out in parallel in multiple (3ˆ) 150 mm tissue culture dishes (Corning). Upon achievement
of 90% cellular confluency, the culture medium (15 mL) was removed and the cells were processed
for the endo-metabolomic analysis. In brief, the cells were extensively washed (4 times) with ice-cold
phosphate-buffered saline (PBS 1X) in order to completely remove any residue of culture medium.
Afterwards, 5.4 mL of PBS were added to each culture dish and cells were collected by scraping with a
rubber policeman. Finally, the cells were counted, placed in Falcon t bes and the final PBS volumes
were adjusted to obtain 15 ˆ 106 cells into 5.4 mL PBS (pH 7.4). On the other side, the culture medium
of each cell growth was collected and immediately stored at ´80 ˝C to be used, in the close future, for
the exo-metabolome analyses.
2.3. Anti-Cancer Drug Treatments
The dose and drug exposure duration time of cell culture for compounds 1 and 2 were established
according to the literature (IC50) [26], while the optimal conditions for compound 3 were chosen on
the basis of in-house unpublished results. In order to have a unique group of untreated control cells
valid for all three treatments, compounds 1 and 2 were added to cell cultures 24 h after seeding. Cells
were exposed to the drug treatment for 72 h with 1 µM final concentration; compound 3 was added to
cell cultures 80 h after seeding. In this case, the drug exposure of cell cultures was for 16 h with 0.1 µM
final concentration. Thus, all the cells (including controls) were detached from the plates after 96 h.
2.4. Cell Metabolome Quenching
The Falcon tubes containing the detached cells were immersed into liquid nitrogen upon complete
freezing of the samples and then slowly thawed in an ice bath. Finally, to destroy the cell membrane
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favoring the release of the intracellular metabolites, the quenched cells were lysed by sonication
(3 short-pulse cycles of 30 s each, at maximum power).
2.5. Metabolites Extraction for NMR Analysis
Intracellular metabolites were extracted using a dual phase extraction procedure introduced by
Bligh and Dyer in 1959 [27] with slight modifications. Adding 6 mL of cold methanol (´20 ˝C) and
6 mL of chloroform to the original solution (5.4 mL) containing quenched cells, briefly a mixture of
water, methanol and chloroform in the volume ratio of 0.9:1:1 was obtained, corresponding to a total
volume of 17.4 mL. Afterwards, this mixture containing quenched and lysed cells was incubated for
20 min on ice and vortexed frequently to facilitate the extraction. The cell extracts were centrifuged
at 4000 g at 4 ˝C for 20 min. This extraction procedure generated a two-phase extract that can be
described as follow: the aqueous upper phase contains water-soluble intracellular metabolites, while
apolar metabolites as lipid molecules are in the organic lower phase. Proteins and macromolecules are
trapped in the thin skin-like layer between the two phases. The upper and lower phase were separated
and carefully transferred into different falcon tubes. Eventually, solvents were completely removed
from both fraction using a vacuum concentrator (hydrophylic phase) and under a gentle flow of N2
gas (organic phase). Only the hydrophilic phase has been taken into account in this study while the
organic phase has been stored at ´80 ˝C for future analysis.
2.6. Sample Preparation for NMR Analysis
Each aqueous cell extract was dissolved in 540 µL of D2O together with 60 µL of a D2O solution
containing the sodium salt of (trimethylsilyl) propanoic-2,2,3,3-d4 acid (TSP) (0.1% w/v), used as
internal chemical shift reference (δH 0.00 ppm), to give a final concentration of 0.6 mM. Samples were
vortexed briefly and transferred into 5-mm NMR tubes.
2.7. NMR Spectroscopy of Cell Extracts
All one-dimensional 1H-NMR spectra were acquired at 300 K on a Bruker Avance III 600 MHz
ultrashielded spectrometer (Bruker Biospin Gmbh, Rheinstetten, Germany) operating at 600.13 MHz
for protons (14.09 Tesla) equipped with a double tuned cryo-probe (TCI) set for 5 mm sample tubes.
1H NMR spectra of hydrophilic cell extracts were acquired using a one-dimensional NOESY-presat
pulse sequence (RD-90˝-t-90˝-tm-90˝-ACQ). All the experiments were acquired with an acquisition
time of 2.73 s, a relaxation delay of 4 s, mixing time of 10 ms, receiver gain of 181, 128 scans, 128 K
data points and a spectral width of 18,029 Hz (30.041 ppm). All samples were automatically tuned,
matched and shimmed.
Representative samples of treated cell extracts were examined by two-dimensional spectroscopy
(JRES, COSY, TOCSY, HSQC and HMBC) to ensure the unambiguous assignment of the metabolites.
A 700 MHz Varian Unity Inova spectrometer equipped with a 5 mm 1H{13C/15N} triple resonance
probe was used for the acquisition of two-dimensional NMR experiments.
2.8. NMR Data Reduction and Processing
Prior to Fourier transformation, each free induction decay (FID) was zero-filled to 128 K points
and multiplied by an exponential function equivalent to a 1.0 Hz line broadening. The resulting spectra
were phase and baseline corrected automatically using TOPSPINTM (Bruker Biospin) and the ppm
scale was referenced according to the TSP peak at 0.00 ppm.
The NMR regions above 9.43 ppm and below 0.8 ppm were removed because they only contain
noise. Furthermore, the region between 4.75 and 4.62 ppm was also removed because containing
the residual water signal. Since NMR spectra showed misalignments in chemical shift due to
pH-sensitive peaks, the spectra were aligned using the interval correlation optimized shifting algorithm
(icoshift) [28]. A normalization preprocessing step was carried out to correct variations of the overall
concentrations of the samples. Since no quantitative internal standard was used, each spectrum of
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the aligned NMR data matrix was normalized to unit area, obtained dividing every variable of each
spectrum by the sum of the absolute value of all its variables. All preprocessing steps were performed
using Matlab (2012b, The Mathworks Inc., Natick, MA, USA).
2.9. Multivariate Data Analysis
The normalized data matrix was imported into Simca-P 13.0 (Umetrics, Umeå, Sweden) and
Pareto-scaled [29]. The number of principal components (PCs) of the Principal Component Analyses
(PCA) [30] was determined by leave one out cross-validation [31]. The quality of the models
was described by the squared Pearson correlation coefficient R2 and Q2 values. R2 is defined as
the proportion of variance in the data explained by the models and indicates the goodness of fit.
Q2 is defined as the proportion of variance in the data predictable by the model and indicates
predictability [29]. Both R2 and Q2 vary between 0 and 1: a good prediction model is indicated
by Q2 > 0.5, whereas a Q2 > 0.9 means an excellent predictive ability of the model. In this study, all
PCA models performed showed a R2 ě 0.9 and a Q2 ě 0.8, which means goodness of fit and goodness
of prediction of the models.
2.10. Metabolite Identification
Identification of hydrophilic metabolites was achieved by (i) comparison with the chemical
shifts of the metabolites in the Human Metabolome Database (HMDB) [32]; (ii) peak fitting routine
within the spectral database in Chenomx NMR Suite 5.0 software package (Chenomx, AB, Canada);
(iii) analysis of literature data [33–35]; (iv) the interpretation of the bi-dimensional NMR spectra; and
(v) the analysis of the Statistical Total Correlation Spectroscopy (STOCSY) [36].
2.11. Statistical Total Correlation Spectroscopy Analysis
Statistical Total Correlation Spectroscopy (STOCSY) analysis (Figure S1) was performed on the
binned (0.02 ppm) NMR (1D-NOESY) data set containing all samples, to obtain the correlations among
the metabolite signals. The results were plotted using a threshold value of R > 0.95.
2.12. Metabolic Pathways Identification
The impact of drug treatment of HCT116 colorectal carcinoma cell line on metabolic pathways
was evaluated using a tool for metabolomic data analysis, which is available online [37]. The Pathway
Analysis module combines results from powerful pathway enrichment analysis with the pathway
topology analysis to help researchers identify the most relevant pathways involved in the conditions
under study. By uploading the discriminatory compounds that were significantly influenced by drug
treatment, the built-in Homo sapiens (human) pathway library for pathway analysis and hypergeometric
test for over-representation analysis were employed. Results were then presented graphically as well
as in a detailed table (Figure S2).
2.13. Statistics
Values are presented as the mean˘ SD. Differences between data sets were analyzed by a one-way
ANOVA, and p < 0.05 was considered to be statistically significant.
3. Results and Discussion
3.1. Optimization of the Quenching and Extraction Procedures
This investigation was aimed to verify the feasibility of the study of the metabolome of human
colon cancer cell line (HCT116) by NMR when treated with anti-cancer drugs. Mammalian cell
metabolomics is an emerging research field, however the number of studies concerning quenching
and extraction methods for HCT116 cells is still limited and generally referred to studies performed by
GC-MS and LC-MS.
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In this study, several published protocols for NMR-based metabolomic analysis to recover the
cell metabolome were tested and the best results were achieved by selecting and combining different
steps described in the diverse procedures [38] (Figure 2A). By analyzing and investigating the different
extraction protocols, a number of critical passages that required an extensive optimization were
identified. For example, the effects of cell quenching in liquid nitrogen were thoroughly investigated.
This commonly represents the first step in several extraction protocols (immediately after the growth
medium removal) just before cell washing to remove the medium residues. However, in this study
it was observed that washing the HCT116 cells after the quenching step turned in to a significant
loss of the cell metabolites, presumably because the freezing step induces the cell wall breakage with
consequent metabolite leakage. To overcome this problem, the order of quenching and washing was
inverted. Moreover, as the HCT116 cells grow as a sub-confluent monolayer, it was found particularly
difficult to completely remove the cell growth medium during the washing step. In particular, one
of the most abundant components of the medium, glucose, challenged the spectral interpretation of
the extracted metabolome due to its residual signals spread all over the central region of the NMR
spectrum. In order to avoid this, the number of washing steps was increased to four. After this
intense washing procedure, the cells could be detached from the dishes by mechanical scraping and
the metabolic activity of the cells immediately quenched by liquid nitrogen. The optimized protocol is
summarized in Figure 2A, and can be recapitulated in the following main steps: (i) growth of the cell
culture; (ii) abundant washing; (iii) cell scraping; (iv) quenching in liquid nitrogen; (v) cell lysis by
sonication; and (vi) dual phase extraction procedure of the metabolites. Experimental description of
these steps is reported in Material and Methods Section.
3.2. Experimental Design
In order to reduce bias in the interpretation of the experiments, it was decided to produce three
biological replicates for each treatment (namely with compounds 1–3). Furthermore, three control
samples (untreated ones) were also collected (CTLa´c). Thus, a total of 12 samples were produced and
studied by high-resolution 1H NMR. The whole design of experiment is summarized in Figure 2B. The
most efficient dose and drug exposure duration time of cell culture were used for each compound.
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Table 1. NMR assignment of the identified metabolites. The values indicate the percentage of increment
or decrement in signal intensity of any given metabolite upon treatment with respect of the control. The
values reported in talics are not statistically significant to be taken into account since the percentage of
variation is less than three times the standard deviation (arbitrary threshold).
Identification
Number Metabolites
Chemical Shifts
(ppm) Compound 1 Compound 2 Compound 3
1 Lactate
1.33(d)
+19% ˘ 4% +165% ˘ 18% +18 ˘ 10%4.13(q)
2 Threonine
1.34(d)
+14% ˘ 4% ´46% ˘ 2% +17 ˘ 8%4.27(m)
3 Tyrosine
6.91(m)
+28% ˘ 3% ´36% ˘ 3% +17˘5%7.21(m)
4 Phenylalanine
7.34(d)
+23% ˘ 1% ´34% ˘ 2% +13% ˘ 3%7.39(m)
7.44(m)
5 Creatine
3.04(s)
+23% ˘ 2% +49% ˘ 10% +19% ˘ 5%3.95(s)
6 Creatine phosphate
3.05(s) ´13% ˘ 5% ´55% ˘ 2% 0 ˘ 9%3.96(s)
7 Glycine 3.58(s) ´8% ˘ 4% ´43% ˘ 4% +6 ˘ 9%
8 Alanine
1.49(d)
+2% ˘ 3% ´29 ˘ 5% +15 ˘ 9%3.81(q)
9 Acetate 1.92(s) 0 ˘ 20% +14% ˘ 1% 0% ˘ 50%
10 Succinate 2.39(s) +7% ˘ 1% +122% ˘ 122% +13% ˘ 1%
11 AMP
4.02(dd)
+5 ˘ 4% ´36 ˘ 5% +16% ˘ 8%
4.36(dd)
4.51(dd)
8.28(s)
8.59(s)
12 Isoleucine, Leucine,Valine
0.94(t)
+29% ˘ 4% ´11% ˘ 5% +15% ˘ 9%
1.02(d)
0.97(d)
0.99(d)
1.05(d)
13 O-Phosphocholine
3.23(s) ´68% ˘ 1% ´61% ˘ 1% +21% ˘ 7%4.17(m)
14 Glycerophosphocholine 3.24(s) ´20% ˘ 2% ´33% ˘ 4% ´1% ˘ 6%
15
Nicotinic acid
adenine
dinucleotide
(NAAD)
8.06(t)
´12% ˘ 2% ´48% ˘ 3% +15% ˘ 2%
8.15(s)
8.42(s)
8.75(d)
8.95(d)
9.13(s)
16 NAD+/NADP+
6.10(d)
´8% ˘ 2% +62% ˘ 11% +6% ˘ 6%
8.18(m)
8.84(d)
9.12(d)
9.32(s)
17 Histidine
7.10(d)
+24% ˘ 1% ´52% ˘ 3% +14% ˘ 2%7.86(d)
18 Glutathione
2.97(dd)
+9% ˘ 2% ´43% ˘ 9% +13% ˘ 4%4.57(q)
2.58(m)
19 ATP 8.52(s) ´24% ˘ 7% ´8% ˘ 4% ´26% ˘ 6%
The limited number of independent samples (12) used in this study is not sufficient to draw
general conclusions, However, this represents a significant and necessary feasibility study before
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setting up a much larger project. Indeed, the whole procedure described in Sections 2.2–5 from cell
seeding to metabolites extraction, represents by far the most labor, cost and time intensive part of
the whole study. In order to achieve a satisfactory and reliable result in terms of reproducibility and
growth yield many trials were conducted to perfection the presented protocol. The purpose was to
demonstrate the feasibility of the NMR metabolomics approach by developing a reliable protocol for
cancer cell line metabolomics using a limited number of reliable sample results.
3.3. Metabolic Profile
The 1D 1H NMR spectra were acquired to determine the metabolic fingerprints of the treated and
untreated cancer cells, while 2D homo- and hetero-nuclear NMR experiments were acquired for the
assignment of the metabolites. The metabolite assignment was accomplished by comparing data from
literature, by peak fitting routine within the spectral database in Chenomx NMR software package, by
the analysis of available chemical shifts databases (i.e., HMDB) and by STOCSY correlation analysis
(Figure S1). The results of the assignment are reported in the Table 1 and in Figure 3.
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Figure 3. (A) Full 1H-NMR spectrum of a repres t ti control sample along with the assig ment of
the most intense signals. (B) Expanded region of the spectrum reported in (A) with the assignment of
the less intense metabolites.
The 1D 1H NMR spectra were processed and studied using a completely untargeted and unbiased
multivariate data analytical approach. The aim was to id i y the commonalities i the metabolic
signatures assoc ated with response to treatment for each tested compound. For this reason, a p incipal
component analysis (PCA) was erformed on the NMR spectra. The PCA sc res plot displaying the
two main principal components (PCs) accounting for 86.3% of the variance (PC-1 70.3%, PC-2 16.0%)
is shown in Figure 4A. The PCA scores plot shows that the samples of the cells treated with RHPS4 (2)
are positioned on the extreme right side of the principal direction of variance PC-1 and the samples of
the cells treated with 1, 3 and controls are placed to the left. Along with PC-2, the treatments with 1
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and 3, positioned in the up-left quadrant of the plot, differ from the control samples, which are found
in the bottom-left quadrant.
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Insets in (B,C) are expanded regions of the relative loading plots. Control samples are colored in red;
compound 1, 2 and 3 in blue, dark yellow and green, respectively. Numbers on the loading plots refer
to the NMR assignment reported in Figure 3.
The lo dings plot for the first principal component (Figure 4B) hows h t the samples treated
with 2 are characterized by a higher content of lactate, creatine, acetate, succi ate and NAD+/NADP+,
whereas the concentrations of threonine, glycine, alanine, tyrosine, phenylalanine, leucine, isoleucine,
valine, histidine, creatine phosphate, glycerophosphocholine, O-phosphocholine, glutathione, NAAD
and AMP are lower with the respect of the samples that lie on the left of the plot. The loadings
plot of the second principal component (Figure 4C) is much noisier than that observed for PC-1.
However, it appears that the samples treated with 1 and 3 differ from the control samples by having
a higher content of leucine, isoleucine, valine, tyrosine, phenylalanine and a lower content of ATP.
However, in order to better understan the effect of 1 and 3 on the metabolism of the cancer cells
and to confirm the effect of 2, a direct comparison of the average 1H NMR spectra of the three
replicates for each treatment and controls was performed. The most interesting regions are reported
in Figure 5. This comparison further corroborated the observation done for 2 and revealed that the
treatments with 1 and 3 also caused variation in the content of lactate, threonine, glycine, creatine
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phosphate, glycerophosphocholine, O-phosphocholine, histidine, NAD+/NADP+ and its precursor
NAAD (Figure 5). Specifically, the concentration of lactate, threonine and creatine increases both in
treatments with 1 and 3. Glycine and creatine phosphate both decrease by treatment with 1, whereas
the treatment with 3 shows only a slight increment of creatine phosphate. O-phosphocholine and
glycerophosphocholine were observed to decrease upon treatment with 1, while samples treated with
3 showed only a slight increment of O-phosphocholine. The behavior of NAAD closely resembles that
of creatine phosphate and glycerophosphocholine for all three treatments. On the other hand, histidine
increased in the cell extracts by treatment with compounds 1 and 3. On the contrary, the concentration
of NAD+/NADP+ increased when the cell were treated with compound 3 and decreased by treatment
with 1. Furthermore, the content of acetate and succinate does not vary, while, concentration of ATP
decreases in all three treatments. The behavior of all the cell metabolites is summarized in Table 1.
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3.4. Metabolic Pathways Analysis
As mentioned in the previous paragraph, many metabolites were affected by the treatment with
compounds 1, 2 and 3 (Table 1). In order to identify which metabolic pathways are involved, the
MetaboAnalyst [37] web server was used. This tool suggests the most relevant pathways by uploading
the discriminatory compounds that were significantly influenced by drug treatment. Results are
provided in a so called “metabolic pathway analysis” and a “metabolite set enrichment overview”
(Figure S2).
In particular, compound 2 significantly perturbs the levels of the metabolites that are involved
in mitochondrial activities, compared to the untreated control cells. In fact, among the detected
metabolites, the increased levels of succinate indicate inhibition of Complex I of respiratory chain
of mitochondria useful to convert succinate in fumarate. This event thus impairs TCA cycle and
production of ATP. Furthermore mitochondrion dysfunctions are shown by impaired conversion
of creatine to creatine phosphate that results in further impairment of urea cycle and amino acid
synthesis. Finally, decreased level of ATP and increased level of lactate and acetate are clear signs of
apoptosis [39] and cell death in accordance with the down-regulated glutathione biosynthesis that
suggest an increased reactive oxygen species (ROS) generation and a weakened ability to balance ROS.
The cell death process was further supported by the reduction of choline metabolism that inhibits
protein and DNA synthesis. Compound 1 behaves similarly to compound 2 because of the increase of
lactate, creatine and decrease of creatine phosphate, ATP and glycine, as well as decrement of choline
metabolism (glycerophosphocholine and O-phosphocholine). However, compounds 1 and 3 do not
seem to interfere with TCA cycle, since succinate did not change. Compound 3, similarly to 1 and 2,
drives cell death and apoptosis because of the increased lactate and creatine and decreased ATP.
In summary, the three tested compounds significantly altered the metabolism of the cells. The
NMR data demonstrate that the treatments generally affect amino acid turnover or protein biosynthesis
(alanine, glycine, isoleucine, leucine, valine, tyrosine, phenylalanine, threonine, histidine), tricarboxylic
acid (TCA) cycle and mitochondrial activity (succinate, NAAD, NAD, ATP), urea cycle (creatine,
creatine phosphate), anaerobic metabolism (lactate) and protein and DNA biosynthesis and DNA
repair (choline and phosphocholine). Furthermore, the specific alterations in the choline metabolism by
compounds 1 and 2 indicate that cell death in HCT116 lines is induced interfering with DNA synthesis
and DNA damaged repair and by inhibition of protein synthesis. The NMR data thus strongly suggest
that treatment with compounds 1 and 2 slow down cellular metabolism, aggravate oxidative stress
and reduces DNA synthesis and repair leading to cellular death and apoptosis in accordance with their
anti-cancer activity. Compound 3 also drives cell death and apoptosis due to a general cytotoxicity in
accordance with anti-cancer activity of Adriamycin [40].
4. Conclusions
The implementation of a reliable NMR metabolomics analytical protocol has been quite
challenging, owing to the number of critical steps along the way from cell culture to NMR tubes.
This investigation was aimed at establishing a reliable protocol that describes how to handle the
metabolome of the HCT116 human colon cancer cell line in order to perform a trustworthy metabolomic
NMR analysis. This was pursued by simulating potential drug treatments using a limited number of
“reliable” samples.
The best protocol was selected by combining different analytical procedures reported in
the literature.
The optimized protocol can be summarized in the following main steps: (i) growth of the cell
culture; (ii) abundant washing; (iii) cell scraping; (iv) quenching in liquid nitrogen; (v) cell lysis by
sonication; and (vi) dual phase extraction procedure of the metabolites. It was demonstrated that the
yield of the extraction and the quality of the extracted metabolome is of sufficiently high quality that the
NMR assignment of detectable [41] metabolites could also be accomplished. Furthermore, preliminary
insight into the biological behavior of the three tested anti-cancer compounds were accomplished.
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regions of the STOCSY reporting the main correlations for NAD/NADP, NAAD and Lactate, respectively, Figure
S2: Impact of the treatment with compounds 1-3 (panel A-C, respectively) on metabolic pathways of HCT116 cell,
Table S1: CHEBI codes for the identified metabolites.
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